Xencor (XNCR) Upgraded at BidaskClub
BidaskClub upgraded shares of Xencor (NASDAQ:XNCR) from a strong sell rating to a sell rating in a report released on Wednesday morning.
A number of other equities research analysts have also weighed in on the stock. Zacks Investment Research restated a sell rating on shares of Xencor in a report on Saturday, January 13th. Cantor Fitzgerald began coverage on shares of Xencor in a report on Wednesday, November 29th. They issued an overweight rating and a $33.00 price objective for the company. Piper Jaffray Companies restated a buy rating and issued a $35.00 price objective on shares of Xencor in a report on Sunday, November 12th. ValuEngine lowered shares of Xencor from a hold rating to a sell rating in a report on Monday, October 23rd. Finally, Canaccord Genuity set a $36.00 target price on shares of Xencor and gave the stock a buy rating in a research note on Monday, October 23rd. Three equities research analysts have rated the stock with a sell rating, two have assigned a hold rating and four have assigned a buy rating to the company. The company presently has an average rating of Hold and a consensus target price of $30.80.
Shares of Xencor (NASDAQ XNCR) opened at $23.40 on Wednesday. The firm has a market cap of $1,100.00, a P/E ratio of -23.17 and a beta of 2.09. Xencor has a 1-year low of $18.55 and a 1-year high of $28.64.
In other news, major shareholder John S. Stafford III bought 50,000 shares of the firm’s stock in a transaction that occurred on Thursday, November 2nd. The shares were bought at an average cost of $19.58 per share, with a total value of $979,000.00. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, major shareholder John S. Stafford III bought 150,000 shares of the firm’s stock in a transaction that occurred on Friday, October 27th. The stock was purchased at an average cost of $19.81 per share, for a total transaction of $2,971,500.00. The disclosure for this purchase can be found here. Over the last ninety days, insiders purchased 253,882 shares of company stock worth $5,033,630. 4.14% of the stock is owned by insiders.
A number of institutional investors have recently modified their holdings of XNCR. Great West Life Assurance Co. Can increased its position in Xencor by 158.9% during the 3rd quarter. Great West Life Assurance Co. Can now owns 6,526 shares of the biopharmaceutical company’s stock valued at $150,000 after purchasing an additional 4,005 shares during the period. Legal & General Group Plc increased its position in Xencor by 4.5% during the 2nd quarter. Legal & General Group Plc now owns 8,978 shares of the biopharmaceutical company’s stock valued at $189,000 after purchasing an additional 385 shares during the period. Principal Financial Group Inc. purchased a new position in Xencor during the 3rd quarter valued at $201,000. Citadel Advisors LLC purchased a new position in Xencor during the 2nd quarter valued at $224,000. Finally, Voya Investment Management LLC increased its position in Xencor by 25.4% during the 2nd quarter. Voya Investment Management LLC now owns 16,793 shares of the biopharmaceutical company’s stock valued at $355,000 after purchasing an additional 3,405 shares during the period. 77.50% of the stock is currently owned by institutional investors and hedge funds.
Xencor, Inc is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing engineered monoclonal antibodies to treat severe and life threatening diseases. It has developed two clinical-stage product candidates, using its Immune Inhibitor Fc platform: XmAb5871, which is in two Phase II trials and is being developed for autoimmune disease, and XmAb7195, which is in a Phase I trial and is being developed for asthma and allergic diseases.
Receive News & Ratings for Xencor Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xencor and related companies with MarketBeat.com's FREE daily email newsletter.